NCT01961921 - The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions

TTR-mediated Amyloidosis

Interventions

DRUG

ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

Trial Locations (9)

Clinical Trial Site, Boston

Clinical Trial Site, Rio de Janeiro

Clinical Trial Site, Le Kremlin-Bicêtre

Clinical Trial Site, Marseille

Clinical Trial Site, Münster

Clinical Trial Site, Lisbon

Clinical Trial Site, Porto

Clinical Trial Site, Palma de Mallorca

Clinical Trial Site, Umeå